Overview

Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough

Status:
Completed
Trial end date:
2018-09-06
Target enrollment:
Participant gender:
Summary
Study of the efficacy, safety, and tolerability of serlopitant for the treatment of refractory chronic cough
Phase:
Phase 2
Details
Lead Sponsor:
Menlo Therapeutics Inc.
Vyne Therapeutics Inc.
Treatments:
Serlopitant